Advertisement

Topics

Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9

19:00 EST 1 Mar 2017 | Globe Newswire

EMERYVILLE, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2016, after the market close, and will host a corporate update conference call and webcast on Thursday, March 9th, at 4:30 PM Eastern Time.

 
Thursday, March 9th @ 4:30 PM Eastern Time/1:30 PM Pacific Time
Toll Free:877-675-4750
International:719-325-4867
Conference ID:1061121
Webcast:http://public.viavid.com/index.php?id=122985
  
Replays, available through March 23, 2017:
Domestic:844-512-2921
International:412-317-6671
Replay PIN:1061121
 

About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

For more information, visit www.zogenix.com.

CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...